JPWO2021207054A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021207054A5
JPWO2021207054A5 JP2022560218A JP2022560218A JPWO2021207054A5 JP WO2021207054 A5 JPWO2021207054 A5 JP WO2021207054A5 JP 2022560218 A JP2022560218 A JP 2022560218A JP 2022560218 A JP2022560218 A JP 2022560218A JP WO2021207054 A5 JPWO2021207054 A5 JP WO2021207054A5
Authority
JP
Japan
Prior art keywords
composition
ibudilast
pharma
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521030A (ja
JP2023521030A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025732 external-priority patent/WO2021207054A1/en
Publication of JP2023521030A publication Critical patent/JP2023521030A/ja
Publication of JPWO2021207054A5 publication Critical patent/JPWO2021207054A5/ja
Publication of JP2023521030A5 publication Critical patent/JP2023521030A5/ja
Pending legal-status Critical Current

Links

JP2022560218A 2020-04-06 2021-04-05 イブジラストを用いる、患者におけるマクロファージ遊走性阻止因子の血漿レベルの減少方法 Pending JP2023521030A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063005792P 2020-04-06 2020-04-06
US63/005,792 2020-04-06
PCT/US2021/025732 WO2021207054A1 (en) 2020-04-06 2021-04-05 Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast

Publications (3)

Publication Number Publication Date
JP2023521030A JP2023521030A (ja) 2023-05-23
JPWO2021207054A5 true JPWO2021207054A5 (https=) 2024-04-15
JP2023521030A5 JP2023521030A5 (https=) 2024-04-15

Family

ID=75674991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560218A Pending JP2023521030A (ja) 2020-04-06 2021-04-05 イブジラストを用いる、患者におけるマクロファージ遊走性阻止因子の血漿レベルの減少方法

Country Status (6)

Country Link
US (2) US12213966B2 (https=)
EP (1) EP4132521A1 (https=)
JP (1) JP2023521030A (https=)
CN (1) CN115335049A (https=)
CA (1) CA3174413A1 (https=)
WO (1) WO2021207054A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745814C1 (ru) * 2020-06-05 2021-04-01 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция левилимаба и ее применение
CA3226898A1 (en) 2021-07-26 2023-02-02 Kazuko Matsuda Ibudilast for preventing eye cancer metastasis
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
WO2023150093A1 (en) * 2022-02-01 2023-08-10 Medicinova, Inc. Ibudilast for use in the treatment of post-covid conditions
JP2025523822A (ja) * 2022-07-13 2025-07-25 メディシノバ・インコーポレイテッド イブジラストの注射用製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1106178T3 (da) 1998-08-10 2005-02-28 Kyorin Seiyaku Kk Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose
SG148198A1 (en) 2003-11-21 2008-12-31 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
MX2007006777A (es) 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
CA2653345A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
CA2970273C (en) 2007-07-11 2020-04-14 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
US20110028510A1 (en) * 2009-02-18 2011-02-03 Combinatorx (Singapore) Pte. Ltd. Compositions, Methods, and Kits for Treating Influenza Viral Infections
EP3558301A4 (en) * 2016-12-22 2020-07-29 MediciNova, Inc. METHOD FOR TREATING GLIOBLASTOMA MULTIFORME WITH IBUDILAST
CA3023014C (en) * 2017-11-06 2023-09-26 Stalicla Sa Pharmaceutical composition for treatment of autism
US20190247369A1 (en) * 2018-02-12 2019-08-15 Medicinova, Inc. Methods of suppressing myeloid-derived suppressor cells in patients

Similar Documents

Publication Publication Date Title
JP2023041862A5 (https=)
JP2020033360A5 (https=)
IL274943B1 (en) Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
JP2014515373A5 (https=)
FI3626270T3 (fi) Sydän- ja verisuonitautien hoito
US20230364044A1 (en) Methods of Treating or Preventing Acute Respiratory Distress Syndrome
BR112012015202B1 (pt) uso de iota- e/ou kappa-carragenano junto com um inibidor da neuraminidase, e, composição farmacêutica
EP2796139A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
JPWO2021207054A5 (https=)
JP2016505050A5 (https=)
US12514830B2 (en) Idebenone for the treatment of Acute Respiratory Distress Syndrome (ARDS) in patients diagnosed with a coronavirus infection
JP2022177119A5 (https=)
JP7369523B2 (ja) 中等度~重度のインフルエンザの処置
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物
CN112426529A (zh) I1咪唑啉受体的拮抗剂在解除α2-肾上腺素受体激动剂介导的麻醉作用中的应用
JP2013523844A5 (https=)
US20230346793A1 (en) Compositions and Methods for Treating SARS-CoV-2
RU2018144248A (ru) Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта
WO2021207489A1 (en) Methods and pharmaceutical compositions to treat pulmonary inflammation in infected patients
CN115884770A (zh) 治疗冠状病毒感染的联用药物及治疗方法
CN111544443B (zh) 一种预防或治疗心肌病的药物组合
CN113209104B (zh) Jak3抑制剂在制备治疗急性呼吸窘迫综合症药物中的应用
JPWO2023089328A5 (https=)
JPWO2021211916A5 (https=)
RU2600822C1 (ru) Способ лечения хронического обструктивного бронхита